Pharmacologic vitreolysis

Seminars in Ophthalmology

Volumn 25, Issue 5-6, 2010, Pages 295-302

  Rhéaume, Marc André ^a   Vavvas, Demetrios ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

pharmacology; vitreodynamics; vitreous

Indexed keywords

CHONDROITIN SULFATE; CLOSTRIDIOPEPTIDASE A; COLLAGEN FIBRIL; DISPASE; FIBRILLAR COLLAGEN; FIBRONECTIN; GLYCOSAMINOGLYCAN; HYALURONIC ACID; HYALURONIDASE; LAMININ; MICROPLASMIN; N ACETYLGALACTOSAMINE 4 SULFATASE; PLACEBO; PROTEOGLYCAN; SUBTILISIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ELECTRON MICROSCOPY; EXTRACELLULAR MATRIX; HUMAN; IN VIVO STUDY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULOPATHY; RETINA VEIN OCCLUSION; REVIEW; TREATMENT DURATION; VITRECTOMY; VITREORETINOPATHY; VITREOUS BODY; VITREOUS BODY DETACHMENT; VITREOUS HEMORRHAGE;

ANIMALS; CHONDROITINASES AND CHONDROITIN LYASES; COLLAGENASES; ENDOPEPTIDASES; ENZYMES; FIBRINOLYSIN; HUMANS; HYALURONOGLUCOSAMINIDASE; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATORS; SUBTILISINS; VITRECTOMY; VITREORETINAL SURGERY; VITREOUS BODY;

EID: 78649374551     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2010.518865     Document Type: Review

References (82)

1. th ed. Philadelphia: Elsevier Mosby, 2013-2020.
2. Sebag J. (1989). The Vitreous: Structure, Function, Pathobiology. New York: Springer.
3. Gandorfer A. Objective of pharmacologic vitreolysis. Dev Ophthalmol 2009;44:1-6.
4. Sebag J. Pharmacologic vitreolysis-premise and promise of the frst decade. Retina 2009;29:871-874.
5. Stefánsson E, Novack RL, Hatchell DL. Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 1990;31:284-289.
6. Stefánsson E. Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol 2006;51:364-380.
7. Gandorfer A, Ulbig M, Kampik A. Plasmin-assisted vitrectomy eliminates cortical vitreous remnants. Eye 2002;16:95-97.
8. Sebag J. Pharmacologic vitreolysis. Retina 1998;18:1-3.
9. Goldenberg DT, Trese MT. Pharmacologic vitreodynamics and molecular fux. Dev Ophthalmol 2009;44:31-36.
10. Ranchod TM, Goldenberg DT, Trese MT. Pharmacologic vitreodynamics. Int Ophthalmol Clin 2009;49:135-140.
11. Sebag J. Is pharmacologic vitreolysis brewing? Retina 2002;22:1-3.
12. Bishop PN. Vitreous as a substrate for vitreolysis. Dev Ophthalmol 2009;44:7-19.
13. Bishop PN. Structural macromolecules and supramo-lecular organization of the vitreous gel. Prog Ret Eye Res 2000;19:323-344.
14. Sebag J. Molecular biology of pharmacologic vitreolysis. Trans Am Ophthalmol Soc 2005;103:473-494.
15. Reardon AJ, Le Goff M, Briggs MD, McLeod D, Sheehan JK, Thornton DJ, Bishop PN. Identifcation in vitreous and molecular cloning of opticin, a novel member of the family of leucine-rich repeat proteins of the extracellular matrix. J Biol Chem 2000;275:2123-2129.
16. Ramesh S, Bonshek RE, Bishop PN. Immunolocalisation of opticin in the human eye. Br J Ophthalmol 2004;88:697-702.
17. Hindson VJ, Gallagher JT, Halfter W, Bishop PN. Opticin binds to heparan and chondroitin sulfate proteoglycans. Invest Ophthalmol Vis Sci 2005;46:4417-4423.
18. Comper WD, Laurent TC. Physiological function of connective tissue polysaccharides. Physiol Rev 1978;58:255-315.
19. Scott JE, Chen Y, Brass A. Secondary and tertiary structures involving chondroitin and chondroitin sulphates in solution, investigated by rotary shadowing/electron microscopy and computer simulation. Eur J Biochem 1992;209:675-680.
20. Wang J, McLeod D, Henson DB, Bishop PN. Age-dependent changes in the basal retinovitreous adhesion. Invest Ophthalmol Vis Sci 2003;44:1793-1800.
21. Sebag J. Age-related differences at the human vitreo-retinal interface. Arch Ophthalmol 1991;109:966-971.
22. Kohno T, Sorgente N, Ishibashi T, Goodnight R, Ryan SJ. Immunofuorescent studies of fbronectin and laminin in the human eye. Invest Ophthalmol Vis Sci 1987;28:506-514.
23. Sebag J, Balazs EA. Morphology and ultrastructure of human vitreous fbers. Invest Ophthalmol Vis Sci 1989;30:1867-1871.
24. Bishop PN, Holmes DF, Kadler KE, McLeod D, Bos KJ. Age-related changes on the surface of vitreous collagen fbrils. Invest Ophthalmol Vis Sci 2004;45:1041-1046.
25. Ueno N, Sebag J, Hirokawa H, Chakrabarti B. Effects of visible-light irradiation on vitreous structure in the presence of a photosensitizer. Exp Eye Res 1987;44:863-870.
26. Vaughan-Thomas A, Gilbert SJ, Duance VC. Elevated levels of proteolytic enzymes in the aging human vitreous. Invest Ophthalmol Vis Sci 2000;41:3299-3304.
27. Brown DJ, Bishop P, Hamdi H, Kenney MC. Cleavage of structural components of mammalian vitreous by endogenous matrix metalloproteinase-2. Curr Eye Res 1996;15:439-445.
28. Sebag J. Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol 2004;242:690-698.
29. Sebag J. Vitreoschisis. Graefes Arch Clin Exp Ophthalmol 2008;246:329-332.
30. Sebag J, Gupta P, Rosen RR, Garcia P, Sadun AA. Macular holes and macular pucker: the role of vitreoschisis as imaged by optical coherence tomography/scanning laser ophthal-moscopy. Trans Am Ophthalmol Soc 2007;105:121-129.
31. Jalkh A, Takahashi M, Topilow HW, Trempe CL, McMeel JW. Prognostic value of vitreous fndings in diabetic retinopathy. Arch Ophthalmol 1982;100:432-434.
32. Akiba J, Arzabe CW, Trempe CL. Posterior vitreous detachment and neovascularization in diabetic retinopathy. Ophthalmology 1990;97:889-891.
33. Robison CD, Krebs I, Binder S, Barbazetto IA, Kotsolis AI, Yannuzzi LA, Sadun AA, Sebag J. Vitreomacular adhesion in active and end-stage age-related macular degeneration. Am J Ophthalmol 2009;148:79-82.
34. Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, Binder S. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol 2007;144:741-746.
35. Gandorfer A. Microplasmin-assisted vitrectomy. Dev Ophthalmol 2009;44:26-30.
36. Uemura A, Nakamura M, Kachi S, Nishizawa Y, Asami T, Miyake Y, Terasaki H. Effect of plasmin on laminin and fbronectin during plasmin-assisted vitrectomy. Arch Ophthalmol 2005;123:209-213.
37. Takano A, Hirata A, Inomata Y, Kawaji T, Nakagawa K, Nagata S, Tanihara H. Intravitreal plasmin injection activates endogenous matrix metalloproteinase-2 in rabbit and human vitreous. Am J Ophthalmol 2005;140: 654-660.
38. Verstraeten TC, Chapman C, Hartzer M, Winkler BS, Trese MT, Williams GA. Pharmacologic induction of posterior vitreous detachment in the rabbit. Arch Ophthalmol 1993;111:849-854.
39. Hikichi T, Yanagiya N, Kado M, Akiba J, Yoshida A. Posterior vitreous detachment induced by injection of plas-min and sulfur hexafuoride in the rabbit vitreous. Retina 1999;19:55-58.
40. Gandorfer A, Priglinger S, Schebitz K, Hoops J, Ulbig M, Ruckhofer J, Grabner G, Kampik A. Vitreoretinal morphology of plasmin-treated human eyes. Am J Ophthalmol 2002;133:156-159.
41. Margherio AR, Margherio RR, Hartzer M, Trese MT, Williams GA, Ferrone PJ. Plasmin enzyme-assisted vitrec-tomy in traumatic pediatric macular holes. Ophthalmology 1998;105:1617-1620.
42. Trese MT, Williams GA, Hartzer MK. A new approach to stage 3 macular holes. Ophthalmology 2000;107:1607-1611.
43. Williams JG, Trese MT, Williams GA, Hartzer MK. Autologous plasmin enzyme in the surgical management of diabetic retinopathy. Ophthalmology 2001;108:1902-1905.
44. Sakuma T, Tanaka M, Inoue J, Mizota A, Souri M, Ichinose A. Use of autologous plasmin during vitrectomy for diabetic maculopathy. Eur J Ophthalmol 2006;16:138-140.
45. Kamei M, Tano Y. Tissue plasminogen activator-assisted vitrectomy: surgical drainage of submacular hemorrhage. Dev Ophthalmol 2009;44:82-88.
46. Glacet-Bernard A, Kuhn D, Vine AK, Oubraham H, Coscas G, Soubrane G. Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol 2000;84:609-613.
47. Chen SN, Yang TC, Ho CL, Kuo YH, Yip Y, Chao AN. Retinal toxicity of intravitreal tissue plasminogen activator: case report and literature review. Ophthalmology 2003;110:704-708.
48. Hesse L, Nebeling B, Schroeder B, Heller G, Kroll P. Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy. Exp Eye Res 2000;70:31-39.
49. Hesse L, Choffet J, Kroll P. Tissue plasminogen activator as a biochemical adjuvant in vitrectomy for proliferative vitreoretinopathy. Ger J Ophthalmol 1995;4:323-327.
50. Le Mer Y, Korobelnik JF, Morel C, Ullern M, Berrod JP. TPA-assisted vitrectomy for proliferative diabetic retinop-athy: results of a double-masked, multicenter trial. Retina 1999;19:378-382.
51. Lapchak PA, Araujo DM, Pakola S, Song D, Wei J, Zivin JA. Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke 2002;33:2279-2284.
52. Gandorfer A, Rohleder M, Sethi C, Eckle D, Welge-Lüssen U, Kampik A, Luthert P, Charteris D. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci 2004;45:641-647.
53. Sakuma T, Tanaka M, Mizota A, Inoue J, Pakola S. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. Invest Ophthalmol Vis Sci 2005;46:3295-3299.
54. de Smet MD, Valmaggia C, Zarranz-Ventura J, Willekens B. Microplasmin: ex vivo characterization of its activity in porcine vitreous. Invest Ophthalmol Vis Sci 2009;50:814-819.
55. de Smet MD, Gandorfer A, Stalmans P, Veckeneer M, Feron E, Pakola S, Kampik A. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology 2009;116:1349-1355.
56. Narayanan R, Kuppermann BD. Hyaluronidase for pharmacologic vitreolysis. Dev Ophthalmol 2009;44:20-25.
57. Hikichi T, Kado M, Yoshida A. Intravitreal injection of hyaluronidase cannot induce posterior vitreous detachment in the rabbit. Retina 2000;20:195-198.
58. Wang ZL, Zhang X, Xu X, Sun XD, Wang F. PVD following plasmin but not hyaluronidase: implications for combination pharmacologic vitreolysis therapy. Retina 2005;25:38-43.
59. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR; Vitrase for Vitreous Hemorrhage Study Groups. Pooled effcacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purifed ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005;140:573-584.
60. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR;, Vitrase for Vitreous Hemorrhage Study Groups. Safety results of two phase III trials of an intravitreous injection of highly purifed ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005;140:585-597.
61. Hageman GS, Russell SR. Chondroitinase-mediated disin-sertion of the primate vitreous body. Invest Ophthalmol Vis Sci 1994;35:1260.
62. Staubach F, Nober V, Janknecht P. Enzyme-assisted vitrectomy in enucleated pig eyes: a comparison of hyaluronidase, chondroitinase, and plasmin. Curr Eye Res 2004;29:261-268.
63. Hermel M, Schrage NF. Effcacy of plasmin enzymes and chondroitinase ABC in creating posterior vitreous separation in the pig: a masked, placebo-controlled in vivo study. Graefes Arch Clin Exp Ophthalmol 2007;245: 399-406.
64. Moorhead LC, Radtke N. Enzyme-assisted vitrectomy with bacterial collagenase. Pilot human studies. Retina 1985;5:98-100.
65. Takahashi K, Nakagawa M, Ninomiya H et al. Enzyme-assisted vitrectomy with collagenase. Jpn J Clin Ophthalmol 1993;47:802-803.
66. Stenn KS, Link R, Moellmann G, Madri J, Kuklinska E. Dispase, a neutral protease from Bacillus polymyxa, is a powerful fbronectinase and type IV collagenase. J Invest Dermatol 1989;93:287-290.
67. Tezel TH, Del Priore LV, Kaplan HJ. Posterior vitreous detachment with dispase. Retina 1998;18:7-15.
68. Oliveira LB, Tatebayashi M, Mahmoud TH, Blackmon SM, Wong F, McCuen BW 2nd. Dispase facilitates posterior vitreous detachment during vitrectomy in young pigs. Retina 2001;21:324-331.
69. Jorge R, Oyamaguchi EK, Cardillo JA, Gobbi A, Laicine EM, Haddad A. Intravitreal injection of dispase causes retinal hemorrhages in rabbit and human eyes. Curr Eye Res 2003;26:107-112.
70. Wang F, Wang Z, Sun X, Wang F, Xu X, Zhang X. Safety and effcacy of dispase and plasmin in pharmaco-logic vitreolysis. Invest Ophthalmol Vis Sci 2004;45: 3286-3290.
71. Zhu D, Chen H, Xu X. Effects of intravitreal dis-pase on vitreoretinal interface in rabbits. Curr Eye Res 2006;31:935-946.
72. Nakamura T, Yamagata Y, Ichishima E. Nucleotide sequence of the subtilisin NAT gene, aprN, of Bacillus subtilis (natto). Biosci Biotechnol Biochem 1992;56:1869-1871.
73. Sumi H, Hamada H, Nakanishi K, Hiratani H. Enhancement of the fbrinolytic activity in plasma by oral administration of nattokinase. Acta Haematol 1990;84:139-143.
74. Urano T, Ihara H, Umemura K, Suzuki Y, Oike M, Akita S, Tsukamoto Y, Suzuki I, Takada A. The profbrinolytic enzyme subtilisin NAT purifed from Bacillus subtilis cleaves and inactivates plasminogen activator inhibitor type 1. J Biol Chem 2001;276:24690-24696.
75. Takano A, Hirata A, Ogasawara K, Sagara N, Inomata Y, Kawaji T, Tanihara H. Posterior vitreous detachment induced by nattokinase (subtilisin NAT): a novel enzyme for pharmacologic vitreolysis. Invest Ophthalmol Vis Sci 2006;47:2075-2079.
76. Kamei M, Misono K, Lewis H. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits. Am J Ophthalmol 1999;128:739-746.
77. Barbazetto IA, Liang J, Chang S, Zheng L, Spector A, Dillon JP. Oxygen tension in the rabbit lens and vitreous before and after vitrectomy. Exp Eye Res 2004;78:917-924.
78. Holekamp NM, Shui YB, Beebe DC. Vitrectomy surgery increases oxygen exposure to the lens: a possible mechanism for nuclear cataract formation. Am J Ophthalmol 2005;139:302-310.
79. Quiram PA, Leverenz VR, Baker RM, Dang L, Giblin FJ, Trese MT. Microplasmin-induced posterior vitreous detachment affects vitreous oxygen levels. Retina 2007;27:1090-1096.
80. Sebag J, Buckingham B, Charles MA, Reiser K. Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy. Arch Ophthalmol 1992;110:1472-1476.
81. Sebag J. Abnormalities of human vitreous structure in diabetes. Graefes Arch Clin Exp Ophthalmol 1993;231:257-260.
82. Zhi-Liang W, Wo-Dong S, Min L, Xiao-Ping B, Jin J. Pharmacologic vitreolysis with plasmin and hyaluronidase in diabetic rats. Retina 2009;29:269-274.